Novocure Ltd. (NVCR)

55.08
NASDAQ : Health Technology
Prev Close 57.06
Day Low/High 54.94 / 57.75
52 Wk Low/High 26.02 / 57.82
Avg Volume 475.80K
Exchange NASDAQ
Shares Outstanding 95.77M
Market Cap 5.46B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Medicare Issues Proposed Local Coverage Determination That Provides Coverage Of Optune® For Newly Diagnosed Glioblastoma

Medicare Issues Proposed Local Coverage Determination That Provides Coverage Of Optune® For Newly Diagnosed Glioblastoma

Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD ) that provides coverage of Tumor Treating Fields, or Optune, for...

Novocure Reports First Quarter 2019 Financial Results And Provides Company Update

Novocure Reports First Quarter 2019 Financial Results And Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2019, highlighting continued revenue growth, an advancing clinical pipeline and a strong cash position.

Novocure Announces The International Journal Of Radiation Oncology, Biology, Physics Publishes Data Demonstrating Higher Doses Of Tumor Treating Fields Improved Survival Of Newly Diagnosed Glioblastoma Patients

Novocure Announces The International Journal Of Radiation Oncology, Biology, Physics Publishes Data Demonstrating Higher Doses Of Tumor Treating Fields Improved Survival Of Newly Diagnosed Glioblastoma Patients

Novocure (NASDAQ:NVCR) announced today that the International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, has published the results of an EF-14 post-hoc analysis demonstrating that higher doses of Tumor Treating...

The Expectations Game: Cramer's 'Mad Money' Recap (Monday 4/29/19)

The Expectations Game: Cramer's 'Mad Money' Recap (Monday 4/29/19)

Jim Cramer says a dip ahead of earnings can be the best protection against a hammering when a stock comes in too hot.

Twilio, Aurora Cannabis, Levi's: 'Mad Money' Lightning Round

Twilio, Aurora Cannabis, Levi's: 'Mad Money' Lightning Round

Jim Cramer weighs in on Twilio, Aurora Cannabis, Levi's, Entergy, NovoCure, Marathon Petroleum, Zix, Party City and more.

Novocure Publishes 2018 Annual Report Featuring Company's Vision, Mission And Values

Novocure Publishes 2018 Annual Report Featuring Company's Vision, Mission And Values

Novocure (NASDAQ: NVCR) announced today the publication of its 2018 Annual Report featuring its vision, mission and values, employee stories and videos, business highlights and selected financial information.

Inaugural AACR-Novocure Tumor Treating Fields Research Grant Recipients Announced At AACR Annual Meeting 2019

Inaugural AACR-Novocure Tumor Treating Fields Research Grant Recipients Announced At AACR Annual Meeting 2019

The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta.

Novocure To Report First Quarter 2019 Financial Results

Novocure To Report First Quarter 2019 Financial Results

Novocure (NASDAQ:NVCR) announced today that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.

Novocure Initiates Phase 3 Pivotal Trial In Recurrent Ovarian Cancer

Novocure Initiates Phase 3 Pivotal Trial In Recurrent Ovarian Cancer

Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.

Novocure Announces 48 Presentations And A Symposium Session On Tumor Treating Fields At The American Association For Cancer Research Annual Meeting 2019

Novocure Announces 48 Presentations And A Symposium Session On Tumor Treating Fields At The American Association For Cancer Research Annual Meeting 2019

Novocure (NASDAQ: NVCR) announced today 48 presentations on Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2019, March 29 through April 3, in Atlanta.

Novocure's Chief Science Officer Retires After 17 Years Of Service

Novocure's Chief Science Officer Retires After 17 Years Of Service

Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure's Chief Science Officer and Head of Research and Development, effective May 1, 2019.

Novocure To Participate In Oppenheimer's 29th Annual Healthcare Conference

Novocure To Participate In Oppenheimer's 29th Annual Healthcare Conference

Novocure (NASDAQ:NVCR) announced today that Wilco Groenhuysen, Novocure's Chief Financial Officer, will participate in Oppenheimer's 29 th Annual Healthcare Conference on March 20, 2019, in New York City.

Novocure Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Company Update

Novocure Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and year ended December 31, 2018, highlighting continued revenue growth, anticipated clinical and regulatory milestones and a strong cash position.

Novocure Announces Fourth Quarter And Full Year 2018 Operating Statistics, Preliminary Net Revenues And Provides Company Update

Novocure Announces Fourth Quarter And Full Year 2018 Operating Statistics, Preliminary Net Revenues And Provides Company Update

Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2018.

Novocure To Participate In The 37th Annual J.P. Morgan Healthcare Conference

Novocure To Participate In The 37th Annual J.P. Morgan Healthcare Conference

Novocure (NASDAQ: NVCR) will participate in the 37 th Annual J.P.

Novocure And The AACR Announce Four Inaugural Research Grants To Promote And Support Innovative Research On Tumor Treating Fields

Novocure And The AACR Announce Four Inaugural Research Grants To Promote And Support Innovative Research On Tumor Treating Fields

Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce four inaugural Tumor Treating Fields research grants.

Sub-Group Analysis Of Novocure's EF-14 Phase 3 Pivotal Trial In Newly Diagnosed Glioblastoma Published In Journal Of Neuro-Oncology Demonstrating More Time On Optune® Predicted Increased Survival

Sub-Group Analysis Of Novocure's EF-14 Phase 3 Pivotal Trial In Newly Diagnosed Glioblastoma Published In Journal Of Neuro-Oncology Demonstrating More Time On Optune® Predicted Increased Survival

Novocure (NASDAQ:NVCR) announced today that the results of a retrospective post-hoc sub-group analysis of its EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma (GBM) have been published in the Journal of Neuro-Oncology.

Novocure And Zai Lab Awarded Deal Of The Year At 5th Annual BioCentury China Healthcare Summit In Shanghai, China

Novocure And Zai Lab Awarded Deal Of The Year At 5th Annual BioCentury China Healthcare Summit In Shanghai, China

Novocure (NASDAQ:NVCR) announced today that Novocure and Zai Lab have received the Deal of the Year Award from BayHelix at a ceremony during the 5 th annual BioCentury China Healthcare Summit in Shanghai, China.

Novocure Announces More Than 70 Presentations On Tumor Treating Fields At 23rd Annual Meeting Of The Society For Neuro-Oncology

Novocure Announces More Than 70 Presentations On Tumor Treating Fields At 23rd Annual Meeting Of The Society For Neuro-Oncology

Novocure (NASDAQ: NVCR) today announced more than 70 presentations on Tumor Treating Fields, including five oral presentations, will be featured at the 23rd Annual Meeting of the Society for Neuro-Oncology (SNO) on Nov.

Novocure And Zai Lab To Host Investor Event

Novocure And Zai Lab To Host Investor Event

Novocure (NASDAQ: NVCR) announced today that it will host an investor event with Zai Lab on Nov.

Novocure Reports Third Quarter 2018 Financial Results And Provides Company Update

Novocure Reports Third Quarter 2018 Financial Results And Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the three and nine months ended September 30, 2018.

Lululemon Athletica, Starbucks, Snap: 'Mad Money' Lightning Round

Lululemon Athletica, Starbucks, Snap: 'Mad Money' Lightning Round

Jim Cramer weighs in on Lululemon Athletica, Ollie's Bargain Outlet, Burlington Stores, Snap, Blackstone Group, NovoCure, Starbucks, Weight Watchers and more.

Novocure Founder Professor Yoram Palti And Director Louis J. Lavigne, Jr. Retire From Board Of Directors

Novocure Founder Professor Yoram Palti And Director Louis J. Lavigne, Jr. Retire From Board Of Directors

Novocure (NASDAQ: NVCR) announced today the retirement of Novocure founder Professor Yoram Palti, MD, PhD, and director Louis J.

Higher Delivered Dose Of Tumor Treating Fields To Tumor Bed Associated With Improved Overall Survival In Newly Diagnosed Glioblastoma

Higher Delivered Dose Of Tumor Treating Fields To Tumor Bed Associated With Improved Overall Survival In Newly Diagnosed Glioblastoma

Novocure (NASDAQ: NVCR) announced today results from a post-hoc analysis of Novocure's EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma (GBM) that demonstrated that a higher dose of Tumor Treating Fields delivered to the tumor bed was...

Pancreatology Publishes Results Of The PANOVA Phase 2 Pilot Trial In Advanced Pancreatic Cancer Suggesting Improved Survival Of Patients Treated With Tumor Treating Fields

Pancreatology Publishes Results Of The PANOVA Phase 2 Pilot Trial In Advanced Pancreatic Cancer Suggesting Improved Survival Of Patients Treated With Tumor Treating Fields

Novocure (NASDAQ: NVCR) announced today that the results of its PANOVA phase 2 pilot trial have been published in Pancreatology .

Novocure Announces That The Medicare DME MACs Have Accepted The Local Coverage Determination Reconsideration Request For Optune®

Novocure Announces That The Medicare DME MACs Have Accepted The Local Coverage Determination Reconsideration Request For Optune®

Novocure (NASDAQ: NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma...

Novocure Announces 55 Presentations At European Association Of Neuro-Oncology Meeting 2018

Novocure Announces 55 Presentations At European Association Of Neuro-Oncology Meeting 2018

Novocure (NASDAQ: NVCR) announced today 55 presentations on Tumor Treating Fields at the European Association of Neuro-Oncology (EANO) Meeting 2018, Oct.

Novocure To Report Third Quarter 2018 Financial Results

Novocure To Report Third Quarter 2018 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2018 on Thursday, October 25, 2018, before the U.

TheStreet Quant Rating: D (Sell)